These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
814 related articles for article (PubMed ID: 19483472)
1. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma. Petrella BL; Brinckerhoff CE Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472 [TBL] [Abstract][Full Text] [Related]
2. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Blancher C; Moore JW; Robertson N; Harris AL Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776 [TBL] [Abstract][Full Text] [Related]
3. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720 [TBL] [Abstract][Full Text] [Related]
5. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status. Tumkur Sitaram R; Landström M; Roos G; Ljungberg B J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322 [TBL] [Abstract][Full Text] [Related]
6. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Carroll VA; Ashcroft M Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202 [TBL] [Abstract][Full Text] [Related]
7. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation. Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971 [TBL] [Abstract][Full Text] [Related]
8. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma. Gong K; Zhang N; Zhang K; Na Y Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786 [TBL] [Abstract][Full Text] [Related]
9. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor. Shang D; Liu Y; Yang P; Chen Y; Tian Y Urology; 2012 Apr; 79(4):966.e1-7. PubMed ID: 22341602 [TBL] [Abstract][Full Text] [Related]
10. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status. Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870 [TBL] [Abstract][Full Text] [Related]
11. VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR. Liu C; Liu L; Wang K; Li XF; Ge LY; Ma RZ; Fan YD; Li LC; Liu ZF; Qiu M; Hao YC; Shi ZF; Xia CY; Strååt K; Huang Y; Ma LL; Xu D Oncogene; 2020 May; 39(21):4286-4298. PubMed ID: 32291411 [TBL] [Abstract][Full Text] [Related]
12. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene]. Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350 [TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Krishnamachary B; Zagzag D; Nagasawa H; Rainey K; Okuyama H; Baek JH; Semenza GL Cancer Res; 2006 Mar; 66(5):2725-31. PubMed ID: 16510593 [TBL] [Abstract][Full Text] [Related]
14. Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma. Kong HS; Lee S; Beebe K; Scroggins B; Gupta G; Lee MJ; Jung YJ; Trepel J; Neckers L Mol Pharmacol; 2010 Dec; 78(6):1072-8. PubMed ID: 20813864 [TBL] [Abstract][Full Text] [Related]
15. Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth. Chen L; Xia G; Qiu F; Wu C; Denmon AP; Zi X Sci Rep; 2016 Sep; 6():32582. PubMed ID: 27581364 [TBL] [Abstract][Full Text] [Related]
16. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929 [TBL] [Abstract][Full Text] [Related]
17. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms. Calzada MJ; Esteban MA; Feijoo-Cuaresma M; Castellanos MC; Naranjo-Suárez S; Temes E; Méndez F; Yánez-Mo M; Ohh M; Landázuri MO Cancer Res; 2006 Feb; 66(3):1553-60. PubMed ID: 16452212 [TBL] [Abstract][Full Text] [Related]
18. Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase. Petrella BL; Brinckerhoff CE Mol Cancer; 2006 Dec; 5():66. PubMed ID: 17140440 [TBL] [Abstract][Full Text] [Related]
20. Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases. Steiner P; Hora M; Stehlik J; Martinek P; Vanecek T; Petersson F; Michal M; Korabecna M; Travnicek I; Hes O Virchows Arch; 2013 Feb; 462(2):183-92. PubMed ID: 23296808 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]